Lyell Immunopharma (LYEL) Shares Outstanding (2019 - 2026)

Lyell Immunopharma's Shares Outstanding history runs 8 years deep, the most recent figure standing at $23.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding rose 58.01% year-over-year to $23.3 million; the TTM figure through Mar 2026 stood at $23.3 million (up 58.01% YoY), while the FY2025 annual figure was $21.3 million, up 44.14% from the prior year.
• Shares Outstanding came in at $23.3 million for Q1 2026 at Lyell Immunopharma, up from $21.3 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $251.9 million in Q3 2023 to a low of $12.5 million in Q4 2022.
• A 5-year average of $98.0 million and a median of $19.3 million in 2025 frame the typical range for Shares Outstanding.
• Across the five-year window, Shares Outstanding surged 1276.38% in 2022 and tumbled 94.91% in 2024, its largest moves.
• Lyell Immunopharma's Shares Outstanding stood at $12.5 million in 2022, then gained by 1.75% to $12.7 million in 2023, then climbed by 16.11% to $14.7 million in 2024, then soared by 44.14% to $21.3 million in 2025, then advanced by 9.77% to $23.3 million in 2026.
• According to Business Quant data, Shares Outstanding over the past three periods registered $23.3 million, $21.3 million, and $19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison